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TRPV4 channels are calcium-permeable cation channels that are activated by several phys-
icochemical stimuli. Accordingly, TRPV4 channels have been implicated in the regulation of
osmosensing, mechanotransduction, thermosensation, and epithelial/endothelial barrier
functions. Whether TRPV4 is also mechanistically implicated in melanoma cell proliferation
is not clear. Here, we hypothesized that TRPV4 is expressed in human melanoma and that
pharmacological activation interferes with cell proliferation.
Methodology/Principal findings
TRPV4 functions were studied in melanoma cell lines (A375, SK-MEL-28, MKTBR), immor-
talized non-cancer keratinocytes (HaCaT), and murine 3T3 fibroblasts by patch-clamp,
qRT-PCR, intracellular calcium measurements, cell proliferation, and flow cytometric
assays of apoptosis and cell cycle. The selective TRPV4-activator, GSK1016790A, elicited
non-selective cation currents with TRPV4-typical current-voltage-relationship in all cell
lines. GSK1016790A-induced currents were blocked by the TRPV4-blocker, HC067047.
TRPV4 mRNA expression was demonstrated by qRT-PCR. In A375 cells, TRPV4 activation
was frequently paralleled by co-activation of calcium/calmodulin-regulated KCa3.1 chan-
nels. Light microscopy showed that TRPV4-activation produced rapid cellular disarrange-
ment, nuclear densification, and detachment of a large fraction of all melanoma cell lines
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and HaCaT cells. TRPV4-activation induced apoptosis and drastically inhibited A375 and
HaCaT proliferation that could be partially prevented by HC067047.
Conclusions/Significance
Our study showed that TRPV4 channels were functionally expressed in human melanoma
cell lines and in human keratinocytes. Pharmacological TRPV4 activation in human mela-
noma cells and keratinocytes caused severe cellular disarrangement, necrosis and apopto-
sis. Pharmacological targeting of TRPV4 could be an alternative or adjuvant therapeutic
strategy to treat melanoma progression and other proliferative skin disorders.
Introduction
The transient receptor potential channel subtype 4, TRPV4, is a poly-modally regulated chan-
nel with a considerable Ca2+-permeability that is capable of transducing a broad variety of
physicochemical stimuli into intracellular calcium signals (for extensive review and key papers
see [1,2,3,4,5,6,7]. In biology, the channel has therefore been suggested to serve as physiological
osmo/mechanosensor, thermosensor, in epithelia/endothelia in several tissues, such as e.g.
arteries, lungs, kidneys, and skin (for extensive reviews see [2,8]). Moreover, pharmaceutical
companies have considered TRPV4 a promising drug target to treat disease, e.g. bladder dys-
function [9], sepsis [10], and pulmonary edema [11,12], giving rise to novel selective small mol-
ecule modulators, such as the activator, GSK1016790A [13], and several selective inhibitors [1].
In the following, experimental proof-of-concept studies revealed that inhibition of TRPV4 was
capable of preventing and resolving pulmonary edema caused by heart failure [11], while the
TRPV4-activator, GSK1016790A, produces endothelial/epithelial barrier disruption, lung
edema, and circulatory collapse in rodents [12,14]. In humans, mutations in the TRPV4 gene—
supposedly gain-of-function mutations that may result in cytotoxic calcium-overload—caused
skeletal dysplasia and motor and sensory neuropathies of very variable severity (for in-depth
review see [8]). While the precise physiological or pathophysiological role of TRPV4 and the
precise molecular mechanism regulating activity of the channel remain not well defined yet, the
existing insight suggested substantial cytotoxicity of TRPV4 over-activation.
Today there is not much known about roles of TRPV4 in neo-proliferative disease. So far,
TRPV4 in breast cancer cells has been shown to promote cancer cell extravasation and to be a
marker of poor prognosis of several solid epithelial cancers [15]. In addition, endothelial
TRPV4 has been shown to regulate tumor angiogenesis [16]. However, whether TRPV4 is
directly involved in the regulation of cancer cell proliferation, is unknown.
Melanoma is a skin cancer with high incidence and mortality and it is caused by oncogenic
transformation of melanocytes that are located in the deeper layers of the epidermis and pro-
duce melanin that acts as light absorber, biologically meant to provide photo protection against
UV-radiation of sunlight and subjected to complex local and neuroendocrine regulation (for
in-depth review see [17,18,19,20].
In the present study, we tested the hypothesis that 1) TRPV4 is functionally expressed 5 and
that 2) pharmacological manipulation of TRPV4 interferes with melanoma cell proliferation.
In the following, we show that human melanoma cell lines expressed functional TRPV4
channels and that the TRPV4-activator, GSK1016790A, caused a strong calcium-overload and
cellular disarrangement, increased the rate of apoptosis, and strongly inhibited cell prolifera-
tion/survival. Similarly, GSK1016790A induced apoptosis and impeded proliferation of
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HaCaT keratinocytes, a spontaneously immortalized aneuploid keratinocyte cell line from
human skin. Together, this suggested that pharmacological TRPV4 activators could have util-




The amelanotic A375, melanotic SK-MEL-28 and uveal MKTBR melanoma cell lines, HaCaT
keratinocytes (all gifts from by Dr. Martin-Duque, Aragón Institute of Health Sciences, Zara-
goza), and 3T3 murine fibroblasts (gift of Dr. Arbonés-Mainar, Aragón Institute of Health Sci-
ences, Zaragoza) were cultured in DMEM supplemented with 10% newborn calf serum (NCS)
and streptomycin and penicillin (S/P, all from Biochrom KG, Berlin, Germany). HaCaT cells
were grown in GBMI medium supplemented with 10% NCS and S/P. Melanoma cell lines
were used at passage 17 and at passage 4 for HaCaT. For proliferation and apoptosis assays,
NCS concentration was 1%. For patch-clamp experiments cells were seeded on coverslips and
investigated within 24 h.
Patch-clamp electrophysiology
Membrane currents were measured in the whole-cell configuration using an EPC10-USB
amplifier (HEKA, Electronics, Lambrecht-Pfalz, Germany), a clamp protocol consisting of
voltage pulses (-80,+80, 0 mV, for 200 ms each) and voltage-ramps (-100 to +100, 500 ms),
borosilicate patch-pipettes with a tip resistance of 4–6 MΩ, a high K+ pipette solution contain-
ing 200 nM “free”Ca2+ and a high Na+ bath solution, as described in more detail previously
[21]. For data acquisition and analysis, we used the patch-master program (HEKA). Ohmic
leak currents of up to 1 nS were subtracted where appropriate.
RNA isolation and qRT-PCR studies
RNA from cultured passage 4 HaCaT and passage 17 A375 cells was isolated with TriReagent
(Sigma, Saint-Louis, MO) following the manufacturer’s protocol, and further purified using
RNA Clean-up and concentration Micro-Elute kit (Norgen Biotek, Thorold, Canada). In
another series of experiments, RNA was isolated from frozen aliquots of A373, MKRBR, and
SK-MEL-28. Genomic DNA elimination was accomplished by using Ambion DNA free kit
(Invitrogen, Carlsbad, CA). Quantity and purity of extracted RNA samples were analyzed by
spectrophotometry (NanoDrop 1000, Thermofisher, Waltham, MA) before using them to
reverse transcription or storing them at –80˚C for later use. Isolated RNA samples were ana-
lyzed for integrity and genomic DNA contamination by gel electrophoresis prior to their use
in reverse transcription. For TRPV4 and KCa3.1, reverse transcription was performed using
600 ng and 1500 ng of total RNA, respectively, in a final volume of 20 μl by using the Super-
Script IV reverse transcriptase and random hexamers (both from Invitrogen, Carlsbad, CA)
following the manufacturer’s protocol.
For qPCR, we used 2 μl (TRPV4) and 0.3 μl (KCa3.1) of transcription products, and corre-
sponding amounts for detection of GAPDH as reference gene, and employed the SYBR Select
Master Mix (Applied Biosystems, Foster City, CA) according to the manufacturer’s protocol.
Primers were: KCa3.1-F, 5’-CATCACATTCCTGACCATCG-3’, KCa3.1-R, 5’-ACGTGCTT
CTCTGCCTTGTT-3’, TRPV4-F, 5’-GATCTTTCAGCACATCATCC-3’, TRPV4-R, 5’-GG
TCATAAAGCGAGGAATAC-3’, GAPDH-F, 5’-GGGATCAATGACCCCTTCAT-3’, GAPDH-
R, 5’-GCCATGGAATTTGCCAT-3’. Amplifications were carried out in triplicates using a
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Step One Plus thermocycler (Applied Biosystems, Foster City, CA) and the following cycle
program: 95˚ C, 15 sec and 60˚ C, 60 sec repeated for 40 cycles. Thereafter, a melting curve
was run to verify amplification products. Collected data were analyzed with LinRegPCR soft-
ware [22] and derived Cq values and mean efficiencies of reaction were used to calculate
expression of the gene of interest (GOI) relative to GAPDH using the formula: % of GAPDH =
EfficiencyCq(GAPDH)–Cq(GOI)x100.
Optical mapping of intracellular calcium
A375 or HACAT cells were plated on coverslips and cultured until 90% confluence. Coverslips
were immersed into Tyrode´s solution (in mM, 140 NaCl, 4.5 KCl, 1 MgCl2, 1.8 CaCl2, 10 Glu-
cose, 10 HEPES, pH 7.4) and cells were incubated at 37˚C with Rhod-2 AM (Invitrogen, Carls-
bad, CA) plus Pluronic F127 (20% solution in DMSO, Invitrogen, Carlsbad, CA) at 5 μM for 40
min. Coverslips were washed twice in Tyrode´s solution, and incubated for another 30 min to
allow Rhod-2 AM de-esterification. Measurements were conducted within4 hours at room
temperature. Recordings were conducted over 4 min at a sampling rate of 10 frames per sec.
Compounds or vehicle (DMSO, 0.1%) were slowly washed into the bath solution. Fluorescence
was recorded with a high speed and low noise optical mapping device consisting of a MiCAM
O5-Ultima CMOS camera (SciMedia, Costa Mesa, CA) with a spatial resolution of 240x256 pix-
els, 30x30 μm per pixel, temporal resolution of 1 ms, and a 150 W halogen lamp (HL-151, SciMe-
dia) with a built-in electromagnetic shutter to minimize photo bleaching. Excitation was done at
530 nm. Emitted fluorescence was split with a dichroic mirror (560 nm) and detected with cam-
era equipped with a 575/15 nm band pass filter for Rhod-2 AM fluorescence recordings. Fluores-
cence recordings were analyzed with the BV Ana imaging software (SciMedia). Four regions of
Interest (ROI) were selected, corresponding to four clusters of approx. 30–80 pixels. Average
intensity of fluorescence was analyzed for each ROI and data points were smoothed with a 3x3
pixels spatial median filter. Background fluorescence was subtracted automatically.
Annexin V/PI double-staining assay
Apoptotic cells were quantified by flow cytometry using an Annexin V-FITC detection kit
(Immunostep, Salamanca, Spain). A375 cells were seeded in 6-well plates and grown to 60–
70% confluence. Then cells were treated with DMSO (vehicle) at 0.2%, GSK1016790A (10
nM), or with GSK1016790A and HC067047 (1 μM) for 1 h, 24 h, or 72 h at 37˚C. Thereafter
adherent cells were gently detached by using Accutase (Corning Inc, Corning, NY) and cells
were stained with Annexin V-FITC and propidium iodide (PI) according to the manufactur-
er’s instructions. Cells were measured in a FACSAria flow cytometer (BD Bioscience, Madrid,
Spain) and data were analyzed with the Kaluza Flow Cytometry Analysis Software v1.1 (Beck-
man Coulter, Brea, CA).
Cell viability analysis with trypan blue staining
Cells spontaneously detached after exposition to DMSO (0.2%), GSK1016790A (10 nM) or
GSK1016790A plus HC067047 (1 μM) during 1 h, 24 h or 72 h were collected from cell culture
media and stained with trypan blue (Invitrogen, Carlsbad, CA) to assess viability. Counting
was performed in a Neubauer hemocytometer following standard procedures.
Cell cycle analysis
Cell cycle in A375 cells was analyzed by flow cytometry by assessing cell DNA content. Cells
were harvested after gentle Accutase treatment and centrifuged at 250xg during 5 min. The
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cell pellet was re-suspended in D-PBS (Lonza, Portsmouth, NH) before fixation with ice-cold
ethanol under agitation. Fixed cells were stored at 4˚C for 24 h, then treated with RNAse
(Sigma-Aldrich, Tres Cantos, Madrid, Spain), stained with PI (Sigma-Aldrich), and analyzed
in a Gallios flow cytometer (Beckman Coulter, Brea, CA). Data were analyzed with Modfit LT
v3.3 software (Verity Software House, Topsham, ME).
Giemsa stain
Cells were fixed with 100% methanol and dried. Thereafter, cells were stained with a ready-to-
use Giemsa solution (Sigma-Aldrich) for 30 min followed by extensive washing with deionized
water. Photographs of cells were taken with a digital camera.
To quantify cell detachment, cells in 1 ml supernatant were treated with trypan blue and
viable and non-viable cells were counted with a Neubauer chamber.
Cell proliferation assays
Cell proliferation/survival was spectrophotometrically assessed using the Janus Green B green
assay as described previously with some modifications [23]. Briefly, cells (1500 cells/well) were
seeded in 96-well plates and the compound(s) or the vehicle, DMSO, were added. Vehicle con-
centrations were kept the same for all concentrations of compounds and their combinations.
Cells were formalin-fixed at day 0 (immediately after addition of compounds),1,2, 3, and 4.
Fixed cells were stained for 5 min with 50 μl/well of 0.3% Janus B Green dye (Acros Organics,
Belgium) at room temperature with continuous stirring followed by a washing step with water.
The dye was eluted with 200 μl/well of 0.5 M HCl of hydrochloric acid and top-read measure-
ments of absorbance were performed in a microplate reader (Sinergy HT, Biotek, USA) at 595
nm. Data in Figures are presented as % of control (DMSO) for clarity. For comparisons
absorption values were used.
Compounds
GSK1016790A (N-[(2S)-1-(4-(N-[(2,4-Dichlorophenyl)sulfonyl]-L-seryl)-1-piperazinyl)-
4-methyl-1-oxo-2-pentanyl]-1-benzothiophene-2-carboxamide) and HC067047 (2-Methyl-1-[3-
(4-morpholinyl)propyl]-5-phenyl-N-[3-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide)
were purchased from Tocris Bioscience (Bristol, UK) and 1 mM or 10 mM stock solutions,
respectively, were prepared with DMSO and stored at -20 C. At the day of experimentation, stock
solutions were further stepwise pre-diluted with first DMSO giving concentrations of 0.1 μM-1
mM for GSK1016790A and then 1:10 with the bath solution or culture media. Appropriate
amounts were added to wells or the bath chamber giving final concentrations of 0.01 nM– 10 μM.
The final concentration of DMSO was 0.1% - 0.2%). RA-2 (1,3-Phenylenebis(methylene) bis
(3-fluoro-4-hydroxybenzoate) was synthesized as described previously [21]. SKA-121 (5-Methyl-
naphtho[2,1-d][1,3]oxazol-2(3H)-imine) was a kind gift from Prof. Heike Wulff, Pharmacology at
University of California, Davis. 13b ([3,5-Bis[(3-fluoro-4-hydroxy-benzoyl)oxymethyl]phenyl]
methyl 3-fluoro-4-hydroxy-benzoate) was a kind gift from Prof. Robert Kiss, Laboratoire de Toxi-
cologie, Institut de Pharmacie, ULB, Belgium. All other drugs were purchased from Sigma (Dei-
senhofen, Germany).
Statistics
Data are given as means ± SEM. Data sets were compared with the paired or unpaired Stu-
dent’s T test or ANOVA, where appropriate. P-values of 0.05 were considered statistically
significant.
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Results
Electrophysiological identification of TRPV4 in melanoma cell lines
In whole cell patch-clamp experiments in A375 melanoma cells (Fig 1A and 1B), the
TRPV4-opener, GSK1016790A instantaneously evoked large cation currents that reversed at
slightly positive potentials (Erev,+4 mV, Fig 1A, upper panel). The IV relationship showed
mild outward-rectification with larger currents at +80 mV than at -80 mV and was slightly N-
shaped with a lower slope at potentials ranging from -50 mV to 0 mV. The selective blocker of
TRPV4, HC067047 [11], abolished this current, but it took 3–4 min to achieve full channel
blockade at 1 μM. Together, these biophysical and pharmacological footprints are characteris-
tic for TRPV4 [1,4].
Fig 1. Characterization of TRPV4 channels in A375 melanoma cells. A) Upper panel: Exemplary whole-cell recordings showing activation of TRPV4 channels by
GSK1016790A (200 nM) and inhibition of currents by HC067047 (1 μM). The arrow indicates a positive reversal potential of GSK1016790A-activated currents. Baseline
currents were not considerable inhibited by HC067047. Lower panel: Co-activation of KCa-currents. The right arrow indicates a negative reversal potential (Erev) of ca.
-35 mV of the mixed TRPV4 and KCa current and the left arrow indicates an Erev of ca. -75 mV of the isolated KCa-current after inhibition of TRPV4 currents by
HC067047. The KCa-current was fully blocked by the negative-gating modulator of KCa3.1 channels, 13b (1 μM). B) Upper panel: Mean normalized currents at clamp
potentials of -80 and +80 mV before and after addition GSK1016790A (n = 8, experiments) and after addition of HC067047 (n = 8). Lower panel: Mean mixed TRPV4/
KCa3.1 currents at a clamp potential of 0 mV after addition of GSK1016790A (n = 5) and inhibition of TRPV4 currents by HC067047 (n = 4) and of KCa3.1 currents by
13b (n = 5). C) Quantitative RT-PCR analysis of TRPV4 and KCa3.1 gene expression as percentage of GAPDH expression (replicates, n = 3). Data points are
means ± SEM.
https://doi.org/10.1371/journal.pone.0190307.g001
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In 5 out 8 experiments, TRPV4 activation was accompanied by activation of a K+ current
causing a shift of Erev to more negative values (-35 mV; Fig 1A and 1B, lower panels). Inhibi-
tion of TRPV4 with HC067047 unmasked this K+ current, which then showed strong inward-
rectification and reversed at-75 mV, which is near the K+ equilibrium potential. The nega-
tive-gating modulator of small/intermediate-conductance KCa2/3 channels, 13b (1 μM, Fig 1A
and 1B, lower panels)[24] fully blocked this K+ current. These properties identified this co-
activated K+ channel as the calcium/calmodulin-regulated KCa3.1 channel [25,26,27].
In Fig 1, we demonstrated functional expression of TRPV4 and KCa3.1 in the A375 mela-
noma cells and we additionally determined mRNA expression of TRPV4 and KCa3.1 in these
cells by qRT-PCR (Fig 1C).
Concerning the other two melanotic melanoma lines, MKTBR and SK-MEL-28, we mea-
sured similar TRPV4 currents and found similar expression levels for TRPV4 channels while
KCa3.1 expression appeared to lower to some degree in MKTBR and SK-MEL-2 if compared
to A375 cells (Fig 2 and S1 Fig).
In the non-cancer human keratinocyte line HaCaT, TRPV4 currents were also found, but
inward-rectification was less evident (see summary data in the bar chart in Fig 2), suggesting
co-activation of other perhaps calcium-activated non-selective cation channels with a linear cur-
rent-voltage relationship or Cl- channels, which, however, were not further characterized here.
We did not observe co-activation of KCa3.1 currents. We found mRNA transcripts for both
channels and expression levels were approx. 10-times lower than in A375 (Fig 2, on right).
Together, we proved functional TRPV4 expression in melanoma cells and immortalized
human keratinocytes.
In 3T3 fibroblasts we also found activation of TRPV4 by GSK1016790A and sensitivity of
the current to HC067047. But current amplitudes were considerably smaller than those in the
other cell lines (S3 Fig). Moreover, mRNA expression levels might be low because we did not
see amplification with our 40-cycles qRT-PCR protocol (data not shown).
TRPV4-mediated changes in intracellular calcium
Since TRPV4 is a Ca2+-permeable channel, we next studied TRPV4-mediated increases in
[Ca2+]i in A375 and HaCaT cells by optical mapping (Fig 3A and 3B). GSK1016790A produced
Fig 2. GSK1016790A-induced TRPV4-currents and inhibition by HC067047 in the melanoma lines, MKTBR and SK-MEL-28, and the human non-cancer
keratinocyte line, HaCaT. Data points are means ± SEM (cells, n = 4–6 each). Panel on right: Quantitative RT-PCR analysis of TRPV4 and KCa3.1 gene expression
in HaCaT as percentage of GAPDH expression (replicates, n = 3). Data points are means ± SEM.
https://doi.org/10.1371/journal.pone.0190307.g002
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a fast and long-lasting increase of intracellular calcium in A375 cells. HC067047 reversed
-though incompletely- this response. Similar responses were seen in HaCaT cells, although the
amplitude of the response was approx. half of that seen in A375 cells.
Hence, TRPV4 activation caused strong elevations in [Ca2+]i in these cell lines.
Morphological alteration caused by TRPV4 activation
To determine if activation of TRPV4 has any detrimental effects on A375 melanoma cells, we
next tested whether TRPV4-activation produced alterations in cell morphology and monitored
alive A375 cells under a light microscope over 60 min. As shown in Fig 4A, challenging A375
cells with GSK1016790A produced overt retraction of lamellipodia, rupture of intercellular
junctions, blebbing, and densification of cell nuclei (pyknosis), and cell swelling and detach-
ment. Accordingly, we found a high number of necrotic (non-viable) cells in the supernatant
over a 3-days period (Fig 4B). These immediate and longer-lasting alterations could be pre-
vented by HC067047 to a considerable extent (Fig 4A and 4B). The vehicle, DMSO, or
HC067047 did not affect cell morphology and cell detachment in a significant fashion. Such
alterations were also seen in MKTBR cells (S2 Fig, upper panel on left). In HaCaT keratino-
cytes, GSK1016790A also produced blebbing (S2 Fig, upper panel on right), nuclear densifica-
tion, and high numbers of necrotic (non-viable) cells in the supernatant (S2 Fig, lower panels.
Such morphological alterations were not observed in 3T3 fibroblasts (S3 Fig), which may be
explained by the substantially lower amounts of inducible currents that may not lead to exces-
sive calcium and sodium entry.
Flow cytomteric measurements of TRPV4-mediated apoptosis
To gain further insights into the cytotoxicity of pharmacological TRPV4 activation, we mea-
sured induction of apoptosis over 3 days in the continuing presence of GSK1016790A (Fig 5).
TRPV4 activation increased the percentage of apoptotic cells (Annexin V+) to 45% of all
cells after 1 h, which was significantly different from DMSO-controls (10%; Fig 5A for repre-
sentative plots and Fig 5B for summary data). Of the GSK1016790A-treated apoptotic cells,
15% was in an early stage of apoptosis (Annexin V+/PI-) and the rest was in a late apoptotic
stage, or secondary necrosis (Annexin V+/PI+). When HC067047 was co-administered, per-
centages of all, early, and late apoptotic cells were significantly less (30%). Thus, HC067047
counteracted GSK1016790A-induced apoptosis but did not fully prevent it, which could be
explained by the slow kinetics of channel blockade as mentioned above.
The pro-apoptotic effect of GSK1016790A was still observed after 24 h- and 72 h- exposure,
although the percentage of all apoptotic cells (Annexin V+) progressively decreased, in partic-
ular the percentage of early apoptotic cells, while the percentage of necrotic cells (Annexin V-/
PI+) increased.
Regarding HaCaT cells, we found a similar induction of apoptosis in response to GSK10167
90A (Fig 5C and 5D). Inhibition of TRPV4 by HC067047 prevented these responses to GSK1
016790A in a significant manner and to a similar degree as in A375 cells.
These data show that pharmacological TRPV4 activation produced apoptosis in A375 cells
and HaCaT keratinocytes.
Impact of TRPV4 activation on the cell cycle
We also studied whether GSK1016790A affected progression of A375 cells and HaCaT kerati-
nocytes through the cell cycle (Fig 6). Here, the FACS analysis revealed that the overall lower
number of A375 cells surviving the first 24h of TRPV4 activation had a slightly lower percent-
age of cells in GO/G1 and a slightly higher percentage of cells in S phase but no change in G2/
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M if compared to controls (Fig 6A). Moreover, a noteworthy portion of cells was found in sub-
G1 (necrotic/late apoptotic cells), which is in line with the higher rate of apoptosis mentioned
above. Such cells were not found in DMSO-treated controls. HC067047 did not prevent the
moderate alterations of percentages of cells being in G0/G1 or the S-phase but lowered the per-
centage of cells in sub-G1, which again is in line with the protective effects of this TRPV4
blocker previously seen in the apoptosis assays.
Fig 3. A) Changes of intracellular calcium ([Ca2+i]) in response to TRPV4 activation in A375 cells. Exemplary images of GSK1016790A(1 μM)-induced increase of
[Ca2+i] (upper left panel), its time course (upper panel in middle), and (on right) summary data of % change of fluorescence to GSK1016790A (n = 10 independent
experiments) and in combination with HC067047 (n = 5 independent experiments). HC067047 (10 μM) partially reversed the response. Note that artifacts caused by
compound addition were removed. No change of fluorescence was recorded in the presence of vehicle (DMSO 0.1%, n = 3). B) Lower panel on left: Exemplary images
of changes of intracellular calcium ([Ca2+]i) to TRPV4 activation in HaCaT cells. Note that artefacts caused by compound addition to the bath were removed. In
middle: Time course of changes in [Ca2+]i in response to GSK1016790A (n = 4 independent experiments) alone and in combination with HC067047 (n = 4
independent experiments). The vehicle (DMSO 0.1%, n = 3) produced virtually no response. On right: Summary of data. Data are means ± SEM; P<0.001, Student’s
T test.
https://doi.org/10.1371/journal.pone.0190307.g003
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In HaCaT keratinocytes we found the same alterations of the cell cycle in response to
GSK1016790A and the combination of GSK1016790A and HC067047 (Fig 6B).
Together, these data suggested that pharmacological TRPV4 activation did not interfere
with cell cycle progression of surviving cells in an appreciable fashion.
Impact of TRPV4 activation on cell proliferation and survival
Lastly, we wanted to examine the effect of TRPV4 activation on cell proliferation and survival
of A375 cells and HaCaT keratinocytes. To do this we used the Janus Green assay, a method
for measuring cell proliferation/survival over 5-days. These experiments revealed that TRPV4
activation by GSK1016790A inhibited cell proliferation/survival of A375 cells in a concentra-
tion-dependent fashion. A half maximal effect was obtained at1 nM (Fig 7A, upper panels),
which corresponded well to the previously reported EC50 for channel activation [1,13]. This
Fig 4. Alterations of cell morphology, cell detachment and cell death induced by GSK1016790A. A) Upper two panels: Exemplary light microscopic images
illustrating time course of cell retraction, membrane blebbing (indicated by arrows), and cell detachment during the first hour of exposure to GSK1016790A (1 μM).
HC067047 (1 μM) prevented visibly GSK1016790A-induced changes. HC067047 or vehicle (DMSO) had no visible effect. Lower panel: Giemsa-stained A375 cells
after 1 h exposure to GSK1016790A, in combination with HC067047, or DMSO. Note the densification of nuclei (dark-grey dots indicated by arrows) in
GSK1016790A-treated cells. B) Counts of non-viable, “death” cells in supernatant. Data points are means ± SEM (number of independent experiments, n = 3).
P<0.05 vs. DMSO, #P<0.05 vs. GSK1016790A; Student’s T test.
https://doi.org/10.1371/journal.pone.0190307.g004
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anti-proliferative effect was antagonized, though again not completely by inhibition of TRPV4
(Fig 7A, lower panel on left).
In keeping with the presence of calcium/calmodulin-regulated KCa3.1 channels in A375
cells (Fig 1) and their co-activation in response to GSK1016790A, we also tested whether an
inhibitor of KCa3.1, the 13b-derivate, RA-2 [21], and the KCa3.1-selective activator, SKA-121,
modulated GSK1016790A-induced inhibition of cell proliferation/survival and had effects on
their own (Fig 7A, lower panel on right). RA-2 significantly augmented the impact of
Fig 5. FACS analysis of apoptosis. A) Representative flow cytometry dot plots with double Annexin V-FITC/PI staining for control cells (DMSO 0,2%), cells
exposed to GSK1016790A (10 nM), and cells exposed to GSK1016790A and HC067047 (1 μM) at 1 h, 24 h, and 72 h. B) Summary data. C) Induction of apoptosis in
HaCaT cells and protective effects of HC067047. D) Summary data. P<0.05 vs. Control, #P<0.05 vs. GSK1016790A, ANOVA, n = 3). Data are means ± SEM
(number of independent experiments, n = 3).
https://doi.org/10.1371/journal.pone.0190307.g005
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GSK1016790A, and mildly reduced A375 proliferation/survival on its own. The KCa3.1-activa-
tor, SKA-121, did not modulate the impact of GSK1016790A and had no impact on its own.
So, these data suggested that the effect of TRPV4-activation and KCa3.1-inhibtion were
additive.
HaCaT cell proliferation/survival was similarly impaired by GSK1016790A (Fig 7B) and
HC067047 prevented this. The positive and negative KCa3.1-gating modulators had also no
significant impact, either alone or in combination with GSK1016790A. To the contrary, we
did not see an impact of GSK1016790A on 3T3 fibroblast proliferation (S2 Fig).
Discussion
The present in-vitro study characterized TRPV4 channels in human melanoma cell lines and
keratinocytes and suggests a utility of small molecule TRPV4 activators to impede cell prolifer-
ation and survival. This conclusion is based on following observations: 1. We demonstrated
TRPV4 gene expression and TRPV4 channel membrane function in melanoma cell lines and
non-cancer HaCaT keratinocytes. 2) Pharmacological activation of TRPV4 and ensuing cal-
cium-influx caused immediate cellular disarrangement and cell death in all lines. 3) Pharmaco-
logical channel activation promoted apoptosis and strongly inhibited cell proliferation/
survival.
TRPV4 channel function has previously been described in a variety of tissues such as endo-
thelium, cell layers of circumferential organs, renal epithelium, and skin to name some
[1,2,3,7,8,28,29]. Information about TRPV4 in cancer tissues is scarce. Here, our electrophysi-
ological study provides new knowledge by showing functional expression of TRPV4 channels
Fig 6. Pharmacological TRPV4 activation did not impair the cell cycle in A375 cells (A) and HaCaT keratinocytes (B).
https://doi.org/10.1371/journal.pone.0190307.g006
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in the cell membrane of A375 melanoma cells as undoubtedly concluded from the pharmaco-
logical and biophysical fingerprints of the current (Figs 1 and 2), such as, activation by the
selective activator, GSK1016790A, inhibition of currents by selective inhibitor, HC067047,
mild N-shape IV relationship, and calcium permeability. A similar functional expression and
gene expression of TRPV4 was found in the amelanotic melanoma cell line, A375, and the mel-
anotic melanoma lines MKTBR and SK-MEL-28, which is important to know since melano-
genesis modulates expression of several genes such as the hypoxia-inducible factor-1 and
Fig 7. Impact of GSK1016790A on cell proliferation/survival. A) Upper panel on left: Concentration-dependent reduction of cell proliferation/survival of A375 as
measured by Janus Green-Assay. Upper panel on right: Note that half-maximal inhibition was achieved at ca. 1 nM GSK1016790A for all time intervals, except day-1.
Lower panel on left: HC067047 antagonized the response to GSK1016790A. Lower panel on right: The negative gating-modulator of KCa3.1, the 13b derivate, RA-2
(10 μM) reduced cell proliferation/survival and potentiated the response to GSK1016790A. The positive-gating modulator of KCa3.1, SKA-121, had no effects. Data
points are means ± SEM (n = 6–36 from n = 2–6 independent experiments). B) GSK1016790A impaired proliferation/survival of HaCaT cells. HC067047 partially
antagonized the response. The negative and positive KCa3.1-gating modulators, RA-2 and SKA-121, respectively, did not modulate the response. Data points are
means ± SEM (n = 18; number of independent experiments, n = 3). P<0.05 vs. DMSO, #P<0.05 vs. GSK1016790A; Student’s T test.
https://doi.org/10.1371/journal.pone.0190307.g007
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related pathways and may thus decide on the availability of a specific target or targeted path-
way and/or cancer progression [30].
Similar to reports on TRPV4 in other cell types [31,32], TRPV4 synergistically interacted
with calcium/calmodulin-gated KCa3.1 because the latter channel was co-activated as conse-
quence of TRPV4-mediated calcium-entry (Fig 1). At the molecular level, the finding of
TRPV4-mRNA and of KCa3.1, further supported functional expression of these channels in
A375 cells.
Our calcium imaging experiments (Fig 3) further complemented the experimental evidence
by demonstrating increases of [Ca2+]i following TRPV4 activation and substantial and proba-
bly cytotoxic calcium-overload that could only be partially reversed by TRPV4 blockade.
Non-cancer HaCaT cells also expressed functional TRPV4 channels as proven by patch-
clamp and qRT-PCR. Our qRT-PCR also detected KCa3.1 mRNA-expression but we failed to
record KCa3.1 currents following TRPV4 activation, presumably because of very low mem-
brane expression of functional channels or few KCa3.1-expressing cells. When compared with
A375 cells, mRNA-expression levels for both channels in HaCaT keratinocytes were 10-times
lower. Regarding [Ca2+]i, we likewise demonstrated a strong increase of [Ca
2+]i in response to
GSK1016790A. TRPV4 expression in 3T3 fibroblasts was considerably lower than in the other
cell types, but currents resembled biophysical and pharmacological properties of TRPV4
[1,2,3,4,5,6,7].
A major goal of the present study was to determine whether pharmacological manipulation
of TRPV4 has any consequences for melanoma cell survival and/or proliferation. Here our
study provides new insight as we could show that pharmacological activation of TRPV4 con-
siderably impaired melanoma cell survival and proliferation (Fig 7). Moreover, the effects of
channel activation could be prevented to a large extent by the TRPV4-blocker, HC067047, sug-
gesting that the effects can indeed be attributed to TRPV4-activation. It is noteworthy that
inhibition of TRPV4 had no effect in the present study suggesting that normal physiological
functions of the channel are not required here.
The deleterious effect of TRPV4 channel activation appeared to rely on two temporally dis-
tinct mechanisms: an instantaneous mechanism characterized by immediate cellular disar-
rangement, pyknosis, retraction of lamellipodia, blebbing, cell rounding and detachment (Fig
4), resembling typical features of necrosis. These responses were most likely a consequence of
the strong calcium (and sodium) entry through TRPV4 and, presumably, the concomitant
activation of a broad range of intracellular calcium-dependent pathways including cytoskeletal
re-arrangements and breakdown of ionic gradients. The other mechanism seemed to be the
induction of apoptosis—likewise calcium-dependent—that occurred over longer time interval
(hours to days, Fig 5).
A clear effect on cell cycle progression was, however, not evident.
In summary, it seems to be clear that TRPV4 activation in A375 cells produced substantial
cytotoxicity and it is therefore worth speculating that the cytotoxicity of this or other TRPV4
activators could help to impede melanoma progression and metastasis. However, this needs to
be proven experimentally in future studies.
Considering TRPV4 a thermosensitive channel [5], it might be worth testing the impact of
TRPV4 activation in combination with radiotherapy to enhance the latter’s efficacy, particu-
larly in pigmented melanoma lines. It is also worth testing this together with inhibitors of
melanogenesis that have been demonstrated to enhance efficacy of radiotherapy in pigmented
melanoma [19,33,34].
The apparent and immediate cytotoxicity of TRPV4-activation was not limited to A375
since the other melanoma lines, MKTBR and SK-MEL-28, responded similarly to TRPV4-acti-
vaton within the first hour (S1 Fig). Also, the non-cancer keratinocyte line, HaCaT, was found
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to be sensitive to TRPV4 activation (S1 Fig) since we observed instantaneous membrane bleb-
bing and pyknosis, cell detachment, and necrosis. Again, similar to A375 cells, we found signif-
icant induction of apoptosis.
These findings in HaCaT keratinocytes provided additional evidence that TRPV4 is an epi-
dermal channel that may not only mechanistically linked to barrier functions [2,8], but accord-
ing to the present study also to cell proliferation. From the dermatologist’s perspective,
pharmacological activation of the keratinocyte channel could be a way to halt hyperkeratosis
in autoimmune disease, such as psoriasis. Interestingly, a recent study in rosacea patients sug-
gested pathological relevant roles of TRPV4 in this skin disease, although activation of TRPV4
in mast cells was shown to be the main driver here [35,36]. Another study reported that the fla-
vonoid, baicalein, increased keratin 1 and 10 production by using TRPV4 channels, which fur-
ther supports TRPV4 as potential drug target in skin disease [37].
In keeping with the frequent and apparently calcium-influx dependent co-activation of
KCa3.1 in A375 cells, we found that inhibition of this channel had also anti-proliferative
effects, but they were less pronounced. Still, this is in line with the idea that KCa3.1 has an
oncogenic potential in melanoma, in this regard similar to earlier reports on pro-proliferative
and/or pro-migratory roles and cancer progression promoting role in several other solid can-
cers, like breast, lung, kidney, and pancreatic cancer [23,38,39,40], as well as in chronic lym-
phocytic leukemia [41]. It is noteworthy that also a close relative of KCa3.1, KCa2.3, has been
suggested to play roles, particularly in melanoma motility [42]. In contrast to KCa3.1 inhibi-
tion, activation of KCa3.1 with SKA-121 did not modulate melanoma A375 proliferation (Fig
7), suggesting the amplified channel functions do not play major roles here.
Considering the functional interplay of KCa3.1 and TRPV4 reported here, the anti-prolifer-
ative actions of pharmacological inhibition of KCa3.1 and activation of TRPV4 had additive
effects but no apparent supra-additive, potentiating effects. In contrast, pharmacological activa-
tion of KCa3.1 did not alter the anti-proliferative actions of TRPV4 activation. This suggested
that KCa3.1 co-activation is not a requirement for the alterations caused by pharmacological
TRPV4-activation, but KCa3.1’s normal function may promote on its own A375 mitogenesis,
thus supporting its oncogenic potential and the channel as target for adjuvant treatments [43,44].
In conclusion, our study described expression and function of TRPV4 (and KCa3.1) channels
in melanoma cells and revealed a potential utility of TRPV4-activators as alternative or adjuvant
therapeutic strategy to produce melanoma cell death and to impede tumor progression.
Supporting information
S1 Fig. TRPV4 and KCa3.1 gene expression. Comparative quantitative RT-PCR analysis of
channel expression as percentage of GAPDH expression in A375, SK-MEL-28, and MKTBR
(replicates, n = 3). Data points are means ± SEM.
(PDF)
S2 Fig. Cell morphology. A) Exemplary light microscopic images of GSK1016790A-induced
morphological alterations in MKTBR melanoma cells after 1 h and protective effect of HC067047.
B) Time course of morphological alterations of HaCaT keratinocytes during the first hour of
exposure to GSK1016790A (1 μM). HC067047 (1 μM) prevented GSK1016790A-induced alter-
ations. HC067047 or vehicle (DMSO) had no apparent effect. Lower left panels: Giemsa-stained
HaCaT cells after 1 h exposure to GSK1016790A, in combination with HC067047, or DMSO. On
right: Counts of non-viable, “death” cells in supernatant. Data points are means ± SEM (number
of independent experiments, n = 3).
(PDF)
Pharmacological manipulation of TRPV4 in A375 melanoma cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0190307 January 2, 2018 15 / 19
S3 Fig. Electrophysiological properties of TRPV4 in murine 3T3 fibroblasts. A) Mean
TRPV4-currents activated by GSK1016790A (200 nM) and inhibition by HC067047. Note that
current amplitudes were smaller than in melanoma cell lines and HaCaT cells. Data points are
means ± SEM (n = 5). B) Exemplary whole-cell recording (1 μM). C) Light microscopic images
of 3T3 fibroblast treated with DMSO (vehicle), GSK1016790A (1 μM) alone or in combination
with HC067047 (1 μM), and with HC067047. Note that cells remained morphologically intact.
D) GSK1016790A at 10 μM did not modulate cell proliferation/survival (n = 4).
(PDF)
S1 Appendix. Data TRPV4 currents in SKMEL-28.
(XLS)
S2 Appendix. Data TRPV4 currents in 3T3.
(XLS)
S3 Appendix. Data TRPV4 currents in MKTBR.
(XLS)
S4 Appendix. Data TRPV4 currents in A375.
(XLS)
S5 Appendix. Data TRPV4 currents in HaCaT.
(XLS)
S6 Appendix. Data qRTPCR HACAT A375 MKTBR SKMEL-28.
(XLS)




S9 Appendix. Cell cycle analysis.
(XLS)
S10 Appendix. Dead cells in suspension.
(XLS)
S11 Appendix. Data Janus Green Assay.
(XLS)
Acknowledgments
We wish to thank Andrea Lorda for excellent technical assistance and the Service of Cytometry
and Cell Sorting of the Aragon Health Sciences Institute (IACS). This work was supported by
the European Community [FP7-PEOPLE MC CIG”BrainIK”, to RK]; Department of Industry
& Innovation, Government of Aragon [GIPASC-B105 to ALGO]; by projects TIN2013-41998-
R and DPI2016-75458-R from Spanish Ministry of Economy and Competitiveness (MINECO),
to EP; MULTITOOLS2HEART from CIBER-BBN through Instituto de Salud Carlos III, Spain,
European Social Fund (EU) and Aragón Government through BSICoS group (T96) to EP; by
the European Research Council (ERC), project ERC-2014-StG 638284 to EP; by the project
PI16/02112 from the Instituto de Salud Carlos III to ALGO, and by the Fondo de Investigacion
Sanitaria, Instituto de Salud Carlos III [CB06/07/1036] to RK. KLH received sabbatical support
from the University of Otago.
Pharmacological manipulation of TRPV4 in A375 melanoma cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0190307 January 2, 2018 16 / 19
Author Contributions
Conceptualization: Ralf Köhler.
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